TNFRSF19

Summary

TNFRSF19 (TNF receptor superfamily member 19, HGNC:11915) is a protein-coding gene on chromosome 13q12.12, encoding Tumor necrosis factor receptor superfamily member 19 (Q9NS68). Can mediate activation of JNK and NF-kappa-B.

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is highly expressed during embryonic development. It has been shown to interact with TRAF family members, and to activate JNK signaling pathway when overexpressed in cells. This receptor is capable of inducing apoptosis by a caspase-independent mechanism, and it is thought to play an essential role in embryonic development. Alternatively spliced transcript variants encoding distinct isoforms have been described.

Source: NCBI Gene 55504 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 87 total
• MANE Select transcript: NM_148957

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11915
Approved symbol	TNFRSF19
Name	TNF receptor superfamily member 19
Location	13q12.12
Locus type	gene with protein product
Status	Approved
Aliases	TAJ-alpha, TROY, TAJ, TRADE
Ensembl gene	ENSG00000127863
Ensembl biotype	protein_coding
OMIM	606122
Entrez	55504

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 15 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000248484, ENST00000382258, ENST00000382263, ENST00000403372, ENST00000464735, ENST00000862810, ENST00000862811, ENST00000862812, ENST00000862813, ENST00000862814, ENST00000862815, ENST00000862816, ENST00000862817, ENST00000862818, ENST00000912233, ENST00000960865

RefSeq mRNA: 5 — MANE Select: NM_148957 NM_001204458, NM_001204459, NM_001354985, NM_018647, NM_148957

CCDS: CCDS55893, CCDS9301, CCDS9302

Canonical transcript exons

ENST00000248484 — 10 exons

Exon	Start	End
ENSE00000678937	23667980	23668082
ENSE00000678938	23660365	23660490
ENSE00000678939	23659050	23659214
ENSE00001412384	23668692	23669097
ENSE00001491479	23673372	23676093
ENSE00003463648	23615867	23616045
ENSE00003522899	23593345	23593455
ENSE00003624759	23590150	23590252
ENSE00003661340	23626707	23626792
ENSE00003904322	23570412	23570848

Expression profiles

Bgee: expression breadth ubiquitous, 224 present calls, max score 98.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.9679 / max 345.4536, expressed in 1088 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
134407	4.2906	1028
134401	3.0956	534
134405	0.4131	118
134408	0.3182	157
134409	0.3103	133
134402	0.2203	125
134403	0.1570	71
134404	0.0937	46
134406	0.0415	14
134410	0.0274	9

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper arm skin	UBERON:0004263	98.53	gold quality
upper leg skin	UBERON:0004262	98.27	gold quality
bronchial epithelial cell	CL:0002328	96.93	gold quality
bronchus	UBERON:0002185	96.30	gold quality
skin of hip	UBERON:0001554	95.68	gold quality
mucosa of paranasal sinus	UBERON:0005030	95.25	gold quality
oviduct epithelium	UBERON:0004804	92.98	gold quality
skin of abdomen	UBERON:0001416	92.89	gold quality
ventricular zone	UBERON:0003053	92.87	gold quality
zone of skin	UBERON:0000014	92.44	gold quality
right uterine tube	UBERON:0001302	91.59	gold quality
trachea	UBERON:0003126	91.45	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	91.35	gold quality
skin of leg	UBERON:0001511	91.25	gold quality
stromal cell of endometrium	CL:0002255	91.02	gold quality
nasal cavity mucosa	UBERON:0001826	90.32	gold quality
nipple	UBERON:0002030	89.88	gold quality
left ventricle myocardium	UBERON:0006566	89.23	gold quality
fallopian tube	UBERON:0003889	89.05	gold quality
parotid gland	UBERON:0001831	88.85	gold quality
myocardium	UBERON:0002349	88.65	gold quality
cardiac atrium	UBERON:0002081	87.87	gold quality
right atrium auricular region	UBERON:0006631	87.87	gold quality
heart right ventricle	UBERON:0002080	87.76	gold quality
saliva-secreting gland	UBERON:0001044	87.51	gold quality
cardiac muscle of right atrium	UBERON:0003379	87.36	gold quality
caput epididymis	UBERON:0004358	87.33	gold quality
mammalian vulva	UBERON:0000997	86.70	gold quality
epithelium of nasopharynx	UBERON:0001951	86.37	gold quality
minor salivary gland	UBERON:0001830	86.30	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.51
E-MTAB-7303	no	303.78

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MSC

miRNA regulators (miRDB)

7 targeting TNFRSF19, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-3679-3P	99.64	69.88	1599
HSA-MIR-519A-2-5P	98.78	71.74	1401
HSA-MIR-520B-5P	98.78	71.74	1401
HSA-MIR-3192-3P	98.62	65.80	970

Literature-anchored findings (GeneRIF, showing 24)

• TROY regulates melanoma growth. (PMID:17187358)
• the ternary complex of NgR/TROY/LINGO-1 expressed on astrocytes, macrophages/microglia and neurones, by interacting with Nogo-A on oligodendrocytes, might modulate glial-neuronal interactions in demyelinating lesions of multiple sclerosis (PMID:17239012)
• Findings provide new insights into the pathogenesis of NPC by highlighting the involvement of pathways related to TNFRSF19 and MDS1-EVI1 in addition to HLA molecules. (PMID:20512145)
• TNFRSF19 overexpression in glioma cells activates Rac1 signaling in a Pyk2-dependent manner to drive glioma cell invasion and migration (PMID:20881009)
• The FAM134B and TNFRSF19 showed a dramatically strong synergistic epistasis in explaining the genetic dissection of the susceptibility to complex vascular dementia. (PMID:21127458)
• study demonstrated that TNFR2 and TROY mRNA levels are enhanced in cutaneous squamous cell carcinoma cells compared to healthy ones in a Tunisian population (PMID:22057614)
• TROY is up-regulated in human colorectal cancer cell lines and in intestinal tumors in mice. It functions as a negative modulator of the Wnt pathway in LGR5-positive stem cells. (PMID:23142137)
• Results show aberrant expression and/or signaling by TROY as a contributor to the dispersion of glioblastoma cells and therapeutic resistance. (PMID:23699535)
• the association of RhoGDIalpha with TROY contributed to TROY-dependent RhoA activation and neurite outgrowth inhibition after Nogo-66 stimulation. (PMID:24129566)
• TNFRSF19 may contribute to the development of colorectal tumors with deregulated beta-catenin activity. (PMID:24623448)
• Glioblastoma tumors (GB) with elevated TROY expression have a statistically positive correlation with increased EGFR expression. TROY expression significantly increases the capacity of EGF to stimulate GB cell invasion, whereas depletion of TROY expression blocks EGF stimulation of glioblastoma cell invasion. TROY expression modulates EGFR signaling by facilitating EGFR activation and delaying its internalization. (PMID:29117939)
• Study showed that TNFRSF19 is highly expressed in nasopharyngeal carcinoma (NPC) and is required for cell proliferation and NPC development. TNFRSF19 was not involved in NFkappaB activation or associated with TRAF proteins. TbetaRI was identified as a specific binding partner for TNFRSF19. TNFRSF19 bound the kinase domain of TbetaRI in the cytoplasm, thereby blocking Smad2/3 association with TbetaRI and subsequent sign… (PMID:29735548)
• TROY signaling role in the glioblastoma cell invasion and survival.PDZ-RhoGEF is an effector of TROY signaling. (PMID:30219706)
• isruption of the TROY/RKIP interaction using the TAT-TROY (234-371 aa) protein reduced the glioma development in xenografted mice. This suggests the TROY/RKIP interaction is a potential target for therapy of gliomas. (PMID:30337686)
• TROY may therefore be a new molecular marker to aid in identifying and selecting patients undergoing radical cystectomy who could potentially benefit from multimodal treatment. (PMID:30475756)
• An inverse trend was found between TROY down-regulation and LGR5 up-regulation in gastric cancer tissue. (PMID:30501144)
• three inherited variations at rs17336602 (G>C), rs4770489 (A>G), and rs34354770 (A>C) in 13q12.12 contribute to lung cancer risk and development by declining p53-responsive enhancer-mediated TNFRSF19 activation (PMID:31126313)
• tumor marker tumor necrosis factor receptor superfamily member 19 as part of a four gene transcript score has prognostic value for metastatic-lethal progression in men treated for localized prostate cancer (PMID:31376183)
• Downregulation of TNFRSF19 and RAB43 by a novel miRNA, miR-HCC3, promotes proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma cells. (PMID:32102752)
• TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance. (PMID:32629176)
• Troy/Tnfrsf19 marks epidermal cells that govern interfollicular epidermal renewal and cornification. (PMID:34358453)
• Unique molecular characteristics of NAFLD-associated liver cancer accentuate beta-catenin/TNFRSF19-mediated immune evasion. (PMID:35351523)
• Long noncoding RNA SNHG8 promotes chemoresistance in gastric cancer via binding with hnRNPA1 and stabilizing TROY expression. (PMID:35354542)
• TNFRSF19 within the 13q12.12 Risk Locus Functions as a Lung Cancer Suppressor by Binding Wnt3a to Inhibit Wnt/beta-Catenin Signaling. (PMID:38047807)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tnfrsf19	ENSDARG00000041869
mus_musculus	Tnfrsf19	ENSMUSG00000060548
rattus_norvegicus	Tnfrsf19	ENSRNOG00000014265

Paralogs (2): EDA2R (ENSG00000131080), EDAR (ENSG00000135960)

Protein

Protein identifiers

Tumor necrosis factor receptor superfamily member 19 — Q9NS68 (reviewed: Q9NS68)

Alternative names: TRADE, Toxicity and JNK inducer

All UniProt accessions (1): Q9NS68

UniProt curated annotations — full annotation on UniProt →

Function. Can mediate activation of JNK and NF-kappa-B. May promote caspase-independent cell death.

Subunit / interactions. Associates with TRAF1, TRAF2, TRAF3 and TRAF5. Interacts with LINGO1.

Subcellular location. Membrane.

Tissue specificity. Highly expressed in prostate. Detected at lower levels in thymus, spleen, testis, uterus, small intestine, colon and peripheral blood leukocytes.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9NS68-1	1, TAJ-alpha, TRADEalpha	yes
Q9NS68-2	2, TRADEbeta
Q9NS68-3	3

RefSeq proteins (5): NP_001191387, NP_001191388, NP_001341914, NP_061117, NP_683760* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001368	TNFR/NGFR_Cys_rich_reg	Domain
IPR022342	TNFR_19	Family
IPR034047	TNFRSF19_N	Domain
IPR047526	TNR19/27/EDAR	Family

UniProt features (26 total): disulfide bond 8, sequence conflict 4, sequence variant 3, repeat 3, splice variant 2, topological domain 2, signal peptide 1, chain 1, transmembrane region 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NS68-F1	60.50	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (8): 49–62, 52–72, 75–89, 92–106, 95–114, 117–135, 138–149, 34–46

Glycosylation sites (1): 105

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 212 (showing top): GOBP_EPITHELIUM_DEVELOPMENT, GOBP_RESPONSE_TO_PEPTIDE, GCANCTGNY_MYOD_Q6, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, CAGCTG_AP4_Q5, AACWWCAANK_UNKNOWN, MARTINEZ_RB1_TARGETS_UP, TCF4_Q5, FREAC3_01, MARTINEZ_RB1_TARGETS_DN, GOBP_JNK_CASCADE, IRF1_Q6, RIGGI_EWING_SARCOMA_PROGENITOR_DN

GO Biological Process (6): hair follicle development (GO:0001942), apoptotic process (GO:0006915), JNK cascade (GO:0007254), positive regulation of canonical NF-kappaB signal transduction (GO:0043123), positive regulation of JNK cascade (GO:0046330), tumor necrosis factor-mediated signaling pathway (GO:0033209)

GO Molecular Function (3): tumor necrosis factor receptor activity (GO:0005031), signaling receptor activity (GO:0038023), protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
hair cycle process	1
anatomical structure development	1
skin epidermis development	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
MAPK cascade	1
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
positive regulation of intracellular signal transduction	1
JNK cascade	1
positive regulation of MAPK cascade	1
regulation of JNK cascade	1
cytokine-mediated signaling pathway	1
cellular response to tumor necrosis factor	1
death receptor activity	1
tumor necrosis factor-mediated signaling pathway	1
tumor necrosis factor binding	1
molecular transducer activity	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

730 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TNFRSF19	LINGO1	Q96FE5	996
TNFRSF19	RTN4R	Q9BZR6	994
TNFRSF19	OMG	P23515	942
TNFRSF19	MAG	P20916	839
TNFRSF19	LGR5	O75473	780
TNFRSF19	RTN4	Q9NQC3	751
TNFRSF19	RELT	Q969Z4	722
TNFRSF19	RTN4RL2	Q86UN3	721
TNFRSF19	MIPEP	Q99797	703
TNFRSF19	TNFRSF21	O75509	667
TNFRSF19	NKD1	Q969G9	640
TNFRSF19	NGFR	P08138	625
TNFRSF19	AXIN2	Q9Y2T1	599
TNFRSF19	COX7B2	Q8TF08	589
TNFRSF19	MECOM	Q03112	572

IntAct

16 interactions, top by confidence:

A	B	Type	Score
TNFRSF19	PEBP1	psi-mi:“MI:0915”(physical association)	0.460
TNFRSF19	PHB1	psi-mi:“MI:0915”(physical association)	0.460
TNFRSF19	ARHGDIA	psi-mi:“MI:0915”(physical association)	0.460
TNFRSF19	PHB1	psi-mi:“MI:0403”(colocalization)	0.460
TNFRSF19	PEBP1	psi-mi:“MI:0403”(colocalization)	0.460
TNFRSF19	ARHGDIA	psi-mi:“MI:0403”(colocalization)	0.460
TRAF1	TNFRSF19	psi-mi:“MI:0915”(physical association)	0.400
TNFRSF19	TRAF2	psi-mi:“MI:0915”(physical association)	0.400
TNFRSF19	TRAF5	psi-mi:“MI:0915”(physical association)	0.400
NEK4	E2F8	psi-mi:“MI:0914”(association)	0.350
TNFRSF19	PLD2	psi-mi:“MI:0914”(association)	0.350

BioGRID (80): TNFRSF19 (Synthetic Lethality), CST2 (Affinity Capture-MS), TYK2 (Affinity Capture-MS), KLK10 (Affinity Capture-MS), ZNF101 (Affinity Capture-MS), CALML5 (Affinity Capture-MS), AMY1C (Affinity Capture-MS), CRNN (Affinity Capture-MS), FLG (Affinity Capture-MS), CST1 (Affinity Capture-MS), PHLDB3 (Affinity Capture-MS), ZNF865 (Affinity Capture-MS), ZNF100 (Affinity Capture-MS), PLEKHG4 (Affinity Capture-MS), CST4 (Affinity Capture-MS)

ESM2 similar proteins: A2VE56, A6QPH9, I3LHS8, O08781, O14545, O54836, P0C6S7, Q14CM0, Q3SZY7, Q3U2E2, Q497H0, Q4R3D6, Q4R970, Q58D05, Q5F3F2, Q5FWF5, Q5R7S6, Q5RDJ2, Q5U2M7, Q5VT97, Q66J85, Q68FE8, Q69Z69, Q6DGF4, Q6FIF0, Q6N043, Q6P2K3, Q70EL2, Q7Z6G8, Q8BIZ1, Q8IWR0, Q8K214, Q8K387, Q8N7W2, Q8N9Z9, Q8NA31, Q8ND82, Q8QFX1, Q91YD3, Q96B23

Diamond homologs: Q8BX35, Q9HAV5, Q9JLL3, Q9N092, Q9NS68, O95407, Q08DP3, Q2KI80, Q5FVJ4, Q8BRJ3, Q8BX43, Q8IUW5, Q8K2J7, Q8NC24, Q969Z4, Q90VY2, Q9R187, Q9UNE0, Q5F3A4, O35305

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

87 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	63
Likely benign	7
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1333 predictions. Top by Δscore:

Variant	Effect	Δscore
13:23579531:T:A	donor_loss	1.0000
13:23593343:A:AG	acceptor_gain	1.0000
13:23593344:G:GA	acceptor_gain	1.0000
13:23593344:GT:G	acceptor_gain	1.0000
13:23593344:GTC:G	acceptor_gain	1.0000
13:23593344:GTCAT:G	acceptor_gain	1.0000
13:23615866:GGAAT:G	acceptor_gain	1.0000
13:23616044:GG:G	donor_gain	1.0000
13:23616045:GG:G	donor_gain	1.0000
13:23616046:G:GG	donor_gain	1.0000
13:23616047:T:G	donor_loss	1.0000
13:23626788:GCACT:G	donor_gain	1.0000
13:23659046:TCA:T	acceptor_loss	1.0000
13:23659047:CAGGT:C	acceptor_loss	1.0000
13:23659048:A:AG	acceptor_gain	1.0000
13:23659048:A:C	acceptor_loss	1.0000
13:23659049:G:GG	acceptor_gain	1.0000
13:23659049:GGT:G	acceptor_gain	1.0000
13:23659182:G:GG	donor_gain	1.0000
13:23659210:CAGCT:C	donor_gain	1.0000
13:23659211:AGCT:A	donor_gain	1.0000
13:23659212:GCT:G	donor_gain	1.0000
13:23659212:GCTG:G	donor_gain	1.0000
13:23659213:CT:C	donor_gain	1.0000
13:23659215:G:GG	donor_gain	1.0000
13:23590250:TTGGT:T	donor_loss	0.9900
13:23590251:TGGT:T	donor_loss	0.9900
13:23590252:GGT:G	donor_loss	0.9900
13:23590253:G:GG	donor_gain	0.9900
13:23590253:GTAA:G	donor_loss	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000073601 (13:23589268 A>G), RS1000080530 (13:23656296 C>T), RS1000128939 (13:23640978 T>C), RS1000135042 (13:23663064 G>A,C), RS1000160814 (13:23573205 G>A), RS1000181244 (13:23675720 C>G,T), RS1000190139 (13:23631730 T>G), RS1000195852 (13:23589031 G>A,T), RS1000197902 (13:23656547 A>G), RS1000212706 (13:23606041 G>A,C,T), RS1000222956 (13:23570531 G>A), RS1000332227 (13:23642936 G>A), RS1000341255 (13:23638730 C>G), RS1000372844 (13:23625085 A>T), RS1000377270 (13:23650016 T>G)

Disease associations

OMIM: gene MIM:606122 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST000687_2	Nasopharyngeal carcinoma	2.000000e-09
GCST000687_7	Nasopharyngeal carcinoma	1.000000e-08
GCST001474_4	Hypothyroidism	5.000000e-06
GCST001523_42	Visceral adipose tissue adjusted for BMI	8.000000e-06
GCST002587_19	Blood pressure (smoking interaction)	4.000000e-07
GCST003098_13	Diabetic kidney disease	4.000000e-06
GCST005113_3	Nasopharyngeal carcinoma	5.000000e-10
GCST006585_1711	Blood protein levels	2.000000e-10
GCST006979_1091	Heel bone mineral density	8.000000e-14
GCST006979_1092	Heel bone mineral density	7.000000e-14

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0006335	systolic blood pressure
EFO:0006526	pack-years measurement
EFO:0009270	heel bone mineral density

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Tumour necrosis factor (TNF) receptor family

CTD chemical–gene interactions

83 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression, decreases expression, affects cotreatment	5
Benzo(a)pyrene	increases methylation, affects methylation, decreases expression	5
Valproic Acid	affects expression, decreases expression, increases expression	5
Arsenic	affects expression, decreases expression, increases abundance, affects cotreatment, increases expression	4
Estradiol	affects cotreatment, decreases expression, increases expression	3
bisphenol A	affects expression, decreases expression	2
trichostatin A	affects expression, increases expression	2
mercuric bromide	decreases expression, affects cotreatment	2
Calcitriol	decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Progesterone	affects cotreatment, decreases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
Tretinoin	increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	affects expression, increases expression	2
8-Bromo Cyclic Adenosine Monophosphate	decreases expression, increases expression	2
Cyclosporine	decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
methylmercuric chloride	decreases expression	1
propionaldehyde	decreases expression	1
lead acetate	increases expression	1
sodium arsenate	decreases expression, increases abundance	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
butyraldehyde	decreases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
benzo(e)pyrene	increases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
ferrous chloride	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.